Celltrion

Main menu

Biologics

A New Generation of pharmaceuticals based on Biotechnology

Classification of Biologics

Pharmaceuticals are divided into chemically synthesized pharmaceuticals and biologics. Biologics consist of therapeutic antibodies, peptide- and protein-based pharmaceuticals (genetic recombination or cell culture), cell therapy products, gene therapy products and other biological agents. Among the biologics, therapeutic antibodies in particular pose challenges in development and production due to their intricate molecular structures, yet produce superior effects by specifically targeting disease-causing agents.

Defining Biologics

Biologics cause fewer side effects and possess more impressive effects compared to chemically synthesized pharmaceuticals as they are derived from living cells, proteins or genes. Biologics are generally used in the treatment of a variety of currently incurable diseases including rheumatoid arthritis, cancer and diabetes.

Generics

Generics icon

Rapid, low-cost manufacture and production through chemical synthesis

Chemical Substance

Pharmaceuticals

Pharmaceuticals icon

Living
Cell

Biologics

Biologics icon

Have complex molecular structures requiring high-level development and production yet have the advantages of fewer side effects and enhanced efficacy

1st Generation Biosimilars

Relatively easier manufacturing process and lower production cost compared to therapeutic antibodies

2nd Generation Biosimilars

Complicated cultivation and purification processes resulting in high production costs and prolonged periods of production

Pharmaceuticals

Pharmaceuticals icon

Chemical Substance

Generics
Generics icon

Rapid, low-cost manufacture and production through chemical synthesis

Living Cell

Biologics

Have complex molecular structures requiring high-level development and production yet have the advantages of fewer side effects and enhanced efficacy

Bio
pharmaceuticals

1st Generation Biosimilars

Relatively easier manufacturing process and lower production cost compared to therapeutic antibodies

2nd Generation Biosimilars

Complicated cultivation and purification processes resulting in high production costs and prolonged periods of production

위로 가기